ArticleCureus2026
Conservative Management With Tranexamic Acid for Intrahepatic Pseudoaneurysm After Unsuccessful Biliary Drainage in a Patient on Apixaban.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Conservative management with tranexamic acid (TXA) is known in difficult-to-access pseudoaneurysms, including those of the pulmonary artery, and its broad efficacy is seen in hemorrhagic pathologies such as subarachnoid hemorrhage. We present the case of a 90-year-old woman with paroxysmal atrial fibrillation on apixaban, remote cholecystectomy, and multiple comorbidities (including hypothyroidism, interstitial lung disease, and asthma) who was admitted for right upper quadrant pain, nausea, and laboratory evidence of cholestasis (total bilirubin 3.0 mg/dL, aspartate aminotransferase 250 U/L). Computed tomography was suggestive of choledocholithiasis, and gastroenterology recommended briefly holding apixaban before endoscopic retrograde cholangiopancreatography (ERCP). On hospital day 3, ERCP was abandoned because of an upper esophageal sphincter narrowing and Zenker's diverticulum. Interventional radiology then performed a percutaneous transhepatic cholangiography with a 22-gauge Chiba needle, but nondilated intrahepatic ducts prevented drain placement. Ultimately, a laparoscopic-assisted ERCP achieved successful common bile duct stone extraction. Postprocedurally, the patient's hemoglobin declined from 13.6 to 9.4 g/dL (without transfusions), and abdominal imaging identified a 1.8-cm intrahepatic pseudoaneurysm plus a 4.1-cm peripancreatic hematoma. Diagnostic angiography demonstrated delayed pseudoaneurysm filling without a definable feeding artery suitable for embolization. Given the small lesion and occult arterial source, we administered oral TXA 1,000 mg three times daily to promote thrombosis. Within 48 hours, hemoglobin stabilized around 8.8 g/dL, and repeat CT revealed spontaneous pseudoaneurysm thrombosis. The patient was discharged uneventfully with stable hemoglobin and had no pseudoaneurysm reaccumulation at short-term follow-up. Should TXA have failed, we had discussed a potential percutaneous thrombin injection, which has shown success for endovascularly inaccessible hepatic pseudoaneurysms. This case underscores the risk of iatrogenic bleeding in patients on direct oral anticoagulants who require multiple biliary interventions and highlights how a short course of TXA can be a practical alternative when standard embolization is not feasible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.